{
      "uri": "https://arxiv.universalpublishings.com/id/eprint/65264",
      "date": "2026-01-14",
      "full_text_status": "none",
      "type": "article",
      "id_number": "oai:ojs.pkp.sfu.ca:article/6569",
      "userid": 1,
      "official_url": "https://mjstjournal.com/index.php/mjst/article/view/6569",
      "subjects": [
        "MASLD, MAFLD, fatty liver disease, metabolic syndrome, steatosis, fibrosis, lean MASLD, comorbidities."
      ],
      "metadata_visibility": "show",
      "date_type": "published",
      "ispublished": "pub",
      "note": "Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/6569)",
      "datestamp": "2026-05-26 15:55:32",
      "rev_number": 1,
      "publisher": "Center for Tech and Media Research",
      "dir": "disk0/00/06/52/64",
      "sword_depositor": 1,
      "keywords": "MASLD, MAFLD, fatty liver disease, metabolic syndrome, steatosis, fibrosis, lean MASLD, comorbidities.",
      "eprint_status": "archive",
      "lastmod": "2026-05-26 15:55:32",
      "publication": "Multidisciplinary Journal of Science and Technology",
      "abstract": "Metabolic dysfunction\u2013associated steatotic liver disease (MASLD/MAFLD) is currently recognized as the most prevalent chronic liver disease worldwide and is closely associated with metabolic syndrome components. This article reviews contemporary evidence on the global and regional epidemiology of MASLD, its structural spectrum, phenotypes, risk factors, pathogenesis, and major comorbidities. Data from large-scale meta-analyses indicate that MASLD affects nearly one-third of the adult population, with a steadily increasing prevalence over the past decade. The structural spectrum of the disease ranges from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. Distinct phenotypes, including obesity-related MASLD and lean MASLD, are described, highlighting their clinical and prognostic relevance. Insulin resistance, obesity, and type 2 diabetes mellitus are identified as key drivers of disease development and progression. The findings support the concept of MASLD as a systemic metabolic disorder rather than an isolated liver condition, emphasizing the importance of early risk stratification and personalized preventive and therapeutic strategies.",
      "title": "LITERATURE REVIEW ON THE TOPIC \u201cSTUDYING THE STRUCTURE OF METABOLIC FATTY LIVER DISEASES ON THE EXAMPLE OF ANDIJAN CITY\u201d",
      "status_changed": "2026-05-26 15:55:32",
      "eprintid": 65264,
      "creators": [
        {
          "name": {
            "family": "Isroiljon",
            "lineage": null,
            "honourific": null,
            "given": "Obidjonov"
          }
        },
        {
          "name": {
            "honourific": null,
            "given": "Qodirov",
            "lineage": null,
            "family": "Dilshodbek"
          }
        },
        {
          "name": {
            "family": "Dilmurod",
            "lineage": null,
            "given": "Saliev",
            "honourific": null
          }
        }
      ]
    }